Rezultati - Matthew D. Hellmann

Refine Results
  1. 1
    PD-1/PD-L1 Axis in Lung Cancer

    PD-1/PD-L1 Axis in Lung Cancer od Fernando C. Santini, Matthew D. Hellmann

    Izdano 2018
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Acquired Resistance to Immune Checkpoint Inhibitors

    Acquired Resistance to Immune Checkpoint Inhibitors od Adam J. Schoenfeld, Matthew D. Hellmann

    Izdano 2020
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Chemotherapy remains an essential element of personalized care for persons with lung cancers

    Chemotherapy remains an essential element of personalized care for persons with lung cancers od Matthew D. Hellmann, Bingyu Li, Jamie E. Chaft, Mark G. Kris

    Izdano 2016
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer od Solange Peters, M. Reck, Egbert F. Smit, Tony Mok, Matthew D. Hellmann

    Izdano 2019
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Opportunistic infections in patients treated with immunotherapy for cancer

    Opportunistic infections in patients treated with immunotherapy for cancer od Chrisann Kyi, Matthew D. Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors od Jamie E. Chaft, Matthew D. Hellmann, Moises J. Velez, William D. Travis, Valerie W. Rusch

    Izdano 2017
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers od Jia Luo, Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann

    Izdano 2020
    Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing od Helena A. Yu, Maria E. Arcila, Matthew D. Hellmann, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics

    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics od Gregory S. Phillips, Azael Freites‐Martínez, Jennifer Wu, Donald Chan, Gabriella Fabbrocini, Matthew D. Hellmann, Mario E. Lacouture

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma od Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images

    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images od Jue Jiang, Yu‐Chi Hu, Chia‐Ju Liu, Darragh Halpenny, Matthew D. Hellmann, Joseph O. Deasy, G Mageras, Harini Veeraraghavan

    Izdano 2018
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas

    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas od Juliana Schilsky, Ai Ni, Linda S. Ahn, Sutirtha Datta, William D. Travis, Mark G. Kris, Jamie E. Chaft, Natasha Rekhtman, Matthew D. Hellmann

    Izdano 2017
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types

    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types od Aparna Chhibber, Lingkang Huang, Hong Zhang, Jialin Xu, Rǎzvan Cristescu, Xiao Liu, Devan V. Mehrotra, Judong Shen, Peter Shaw, Matthew D. Hellmann, Alexandra Snyder

    Izdano 2022
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas od Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew J. Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon

    Izdano 2015
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden od Clarissa Mathias, Martin Reck, Matthew D. Hellmann, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth J. O’Byrne, Prabhu Bhagavatheeswaran, Faith E. Nathan, Hossein Borghaei, Luis Paz‐Ares

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib od Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade od Tavi Nathanson, Arun Ahuja, Alex Rubinsteyn, Bülent Arman Aksoy, Matthew D. Hellmann, Diana Miao, Eliezer M. Van Allen, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jeff Hammerbacher

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC od Laurent Dercle, Matthew Fronheiser, Naiyer A. Rizvi, Matthew D. Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H. Schwartz, Binsheng Zhao, David Leung

    Izdano 2023
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers od Anya M. Litvak, Paul K. Paik, Kaitlin M. Woo, Camelia S. Sima, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders od Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan, Sasha Kravets, Suzanne E. Dahlberg, Lydia Gedmintas, Roxana Azimi, Hira Rizvi, Jonathan W. Riess, Matthew D. Hellmann, Mark M. Awad

    Izdano 2018
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: